Supha Pharmachem: NCLT Appoints New RP, Suspends Board Powers

LAWCOURT
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Supha Pharmachem: NCLT Appoints New RP, Suspends Board Powers
Overview

Supha Pharmachem Ltd has a new Resolution Professional, Mr. Raju Mangilal Marshiya, appointed by the NCLT on May 11, 2026. This appointment means Mr. Marshiya now oversees the company's Corporate Insolvency Resolution Process (CIRP), with the powers of the Board of Directors remaining suspended. The NCLT order formalizes the shift in control amidst ongoing financial distress.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Supha Pharmachem: NCLT Appoints New RP, Board Powers Suspended Amid Insolvency

New RP Takes Charge

The National Company Law Tribunal (NCLT) has approved the appointment of Mr. Raju Mangilal Marshiya as the Resolution Professional (RP) for Supha Pharmachem Limited. This order, received by the company on May 11, 2026, formally tasks Mr. Marshiya with leading the ongoing Corporate Insolvency Resolution Process (CIRP). He replaces the Interim Resolution Professional (IRP) and will manage the company's insolvency proceedings. The NCLT had initially ordered CIRP on April 30, 2026.

Why This Matters

Appointing a Resolution Professional marks a key phase in insolvency proceedings. Mr. Marshiya will now guide Supha Pharmachem toward a potential resolution, which may include restructuring, asset sales, or other creditor recovery measures. Crucially, the company's Board of Directors remains suspended, with all authority now vested in the RP.

Company Background

Supha Pharmachem Limited manufactures pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company was admitted into the Corporate Insolvency Resolution Process (CIRP) by the NCLT Ahmedabad, signaling substantial financial distress.

Key Changes

  • Mr. Raju Mangilal Marshiya has assumed full control of Supha Pharmachem's CIRP.
  • The powers of the existing Board of Directors are now suspended.
  • The RP will manage daily operations and explore resolution strategies.
  • The BSE is expected to update its records to reflect the new Insolvency Professional.

Risks to Watch

  • The company's ongoing Corporate Insolvency Resolution Process (CIRP) indicates severe financial distress and operational challenges.
  • The success of the CIRP depends on the viability of proposed resolution plans, the outcome of which remains uncertain.

Peer Comparison

This development concerns a specific insolvency event rather than operational performance, making direct financial peer comparisons less relevant currently.

What to Track Next

  • Actions and proposed plans by the new Resolution Professional.
  • Updates from the Committee of Creditors (CoC) on resolution progress.
  • The official update of Supha Pharmachem's records with the BSE.
  • Any potential bids or expressions of interest from resolution applicants.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.